Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Tyrosine kinase inhibitors (TKIs) have revolutionized epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treatment.
• Treatment resistance to TKIs remains a significant clinical challenge.
• The tumor microenvironment (TME) is a complex ecosystem influencing cancer progression and treatment response.

Purpose of the Study:

• To review the role of the tumor microenvironment (TME) in the development of resistance to TKIs in EGFR-mutant NSCLC.
• To identify interactions between TME components and tumor cells that contribute to TKI resistance.
• To explore TME-targeting strategies as a novel therapeutic approach for overcoming TKI resistance.

Main Methods:

• Literature review of studies investigating TME components and TKI resistance in EGFR-mutant NSCLC.
• Analysis of interactions between tumor cells, immune cells, stromal cells, and non-cellular components within the TME.
• Synthesis of current research on therapeutic strategies targeting the TME.

Main Results:

• Dynamic changes in the TME during TKI treatment are associated with acquired resistance.
• Specific TME components, including immune cells, fibroblasts, vasculature, immune checkpoint proteins, and cytokines, actively promote TKI resistance.
• Understanding these interactions provides insights into potential therapeutic vulnerabilities.

Conclusions:

• The TME is a critical determinant of TKI efficacy and resistance in EGFR-mutant NSCLC.
• Targeting TME components represents a promising strategy to overcome or prevent TKI resistance.
• Further research into TME-directed therapies could lead to improved treatment outcomes for NSCLC patients.